Endocrine Today

Endocrine Today The content you need, when you need it.

Endocrine Today on Healio.com brings readers breaking and industry news related to endocrine health, featuring updates from journals, meetings, industry announcements, FDA updates and clinical perspectives. Designed as an in-depth specialty clinical information website, Healio.com brings medical professionals the best news reporting, dynamic multimedia, question-and-answer columns, CME and other e

ducational activities in a variety of formats, quick reference content, blogs, peer-reviewed journals and a full line of popular book titles.

🗣️“These data reinforce the potential of crinecerfont to reduce glucocorticoid dosing while maintaining androgen control...
06/16/2026

🗣️“These data reinforce the potential of crinecerfont to reduce glucocorticoid dosing while maintaining androgen control and emphasize how decoupling the two may improve long-term outcomes,” Dr. Oksana Hamidi told Healio at ENDO 2026

CHICAGO — At 2 years, crinecerfont demonstrated favorable effects on weight, body composition and insulin resistance in adults with classic congenital adrenal hyperplasia, researchers reported at ENDO 2026.  

🦴 The monoclonal antibody burosumab confers a range of improvements in quality of life for patients with X-linked hypoph...
06/16/2026

🦴 The monoclonal antibody burosumab confers a range of improvements in quality of life for patients with X-linked hypophosphatemia, according to data presented at ENDO 2026.

CHICAGO — Burosumab is tied to greater improvements in pain, stiffness and physical function than active vitamin D and phosphate salts among patients with X-linked hypophosphatemia, according to data presented at ENDO 2026. Burosumab-twza (Crysvita, Kyowa Kirin), a monoclonal anti-fibroblast growt...

📰 In patients with type 2 diabetes, those taking SGLT2 inhibitors had higher risk for major diabetic foot complications ...
06/15/2026

📰 In patients with type 2 diabetes, those taking SGLT2 inhibitors had higher risk for major diabetic foot complications than those on GLP-1s, researchers reported at ENDO 2026.

CHICAGO — Major diabetic foot complications were more common in patients with type 2 diabetes treated with SGLT2 inhibitors than those treated with GLP-1 receptor agonists, researchers reported at ENDO 2026.However, new-onset diabetic peripheral neuropathy was lower in patients taking SGLT2 in...

🔎 Garetosmab 3 mg/kg and 10 mg/kg reduced bone lesion formation and volume in patients with fibrodysplasia ossificans pr...
06/15/2026

🔎 Garetosmab 3 mg/kg and 10 mg/kg reduced bone lesion formation and volume in patients with fibrodysplasia ossificans progressiva at 56 weeks vs. placebo, with no major safety signals.

CHICAGO — Garetosmab reduced new heterotopic bone lesions in patients with fibrodysplasia ossificans progressiva at 56 weeks compared with placebo, according to results of the OPTIMA trial presented at ENDO 2026. “[Fibrodysplasia ossificans progressiva] is an ultrarare disorder that affe...

💉 A once-weekly therapy allowed adults with hypoparathyroidism to maintain normal serum calcium levels without vitamin D...
06/15/2026

💉 A once-weekly therapy allowed adults with hypoparathyroidism to maintain normal serum calcium levels without vitamin D or oral calcium supplementation at 12 weeks.

Learn more about canvuparatide ⬇️

CHICAGO — Most adults receiving a once-weekly hypoparathyroidism therapy were able to maintain normal calcium levels at 12 weeks without active vitamin D and oral calcium supplementation, according to data from a phase 2 trial. Mishaela R. Rubin, MD, assistant professor of clinical medicine at Col...

🚨 The FDA has approved a new indication for Tzield to delay a reduction in endogenous insulin production for children an...
06/15/2026

🚨 The FDA has approved a new indication for Tzield to delay a reduction in endogenous insulin production for children and teens with stage 3 type 1 diabetes.

Learn more about this new approval for teplizumab ⬇️

The FDA has granted accelerated approval for teplizumab-mzwv as the first disease-modifying therapy for children and adolescents with stage 3 type 1 diabetes, according to an industry press release. As Healio previously reported, teplizumab-mzwv (Tzield, Sanofi) was originally approved by the FDA in...

📰 Crincerfont was linked with favorable changes in weight, BMI and insulin resistance in adults with congenital adrenal ...
06/14/2026

📰 Crincerfont was linked with favorable changes in weight, BMI and insulin resistance in adults with congenital adrenal hyperplasia at 2 years, and had positive effects on bone age in youths with CAH.

CHICAGO — At 2 years, crinecerfont demonstrated favorable effects on weight, body composition and insulin resistance in adults with congenital adrenal hyperplasia, researchers reported at ENDO 2026.  

💡 In postmenopausal women, hormone therapy use conferred higher bone mineral density compared with nonuse, researchers r...
06/14/2026

💡 In postmenopausal women, hormone therapy use conferred higher bone mineral density compared with nonuse, researchers reported at ENDO 2026.

CHICAGO — In postmenopausal women, use of menopausal hormone therapy was associated with higher bone mineral density compared with nonuse, according to a study presented at ENDO 2026. “We undertook this study because menopausal hormone therapy (MHT) remains one of the most effective intervention...

🆕 In patients taking at least two antihypertensive medications, those taking a GLP-1 were more likely to have hypotensio...
06/14/2026

🆕 In patients taking at least two antihypertensive medications, those taking a GLP-1 were more likely to have hypotension, especially if they had diabetes or were 65 or older.

CHICAGO — In patients being treated for hypertension, those taking a GLP-1 receptor agonist had higher rates of hypotensive events compared with those not taking one, researchers reported at ENDO 2026. “I began to notice multiple patients in clinic who were started on GLP-1s (by me and others) w...

📉 Adults with type 2 diabetes receiving zenagamtide had a 1.56 percentage point larger decrease in HbA1c compared with p...
06/14/2026

📉 Adults with type 2 diabetes receiving zenagamtide had a 1.56 percentage point larger decrease in HbA1c compared with placebo at 36 weeks.

Read more about this novel drug ⬇️

NEW ORLEANS — A novel unimolecular GLP-1/amylin receptor agonist conferred reductions in HbA1c and body weight for adults with type 2 diabetes, according to data from a phase 2 trial. Zenagamtide (Novo Nordisk) is under investigation for once-weekly subcutaneous and once-daily oral administration ...

Address

West Deptford, NJ

Website

Alerts

Be the first to know and let us send you an email when Endocrine Today posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Endocrine Today:

Shortcuts

Share

Category